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INTRODUCTION 
Human serum albumin (HSA), the most abundant protein in human plasma, 
accounts for about 60% of the total serum proteins (Carter and Ho, 1994). It is 
also distributed to the interstitial fluid of the body tissues. HSA is synthesized in 
the liver, and exported to other parts as a non-glycosylated protein. The protein 
binds to a number of relatively insoluble endogenous compounds such as 
unesterified fatty acids, bilirubin, bile acids etc and thus makes their transport 
easier throughout the circulation (Kragh-Hansen, 1990; Peters, 1995). It also has 
the ability to bind a broad spectrum of drugs, and much of the importance of this 
protein has been referred to as its effects on drug delivery. Drug binding to HSA 
plays an important role in the pharmacokinetics of the drug by limiting the 
unbound concentration and affecting its administration and elimination (Carter 
and Ho, 1994; Peters, 1995). In some cases, the major fraction of the administered 
drug is determined by HSA. For example, warfarin [3-(∝-acetonylbenzyl)-4-
hydroxycoumarin], a widely used anticoagulant drug for the treatment of venous 
thrombosis and pulmonary embolism (Bell and Simon, 1982; Petersen et al., 
1989; Petersen and Kwaan, 1986), as well as in the prevention of prosthetic heart 
valve thromboembolism (Mok et al., 1985), which is 99% bound to the protein 
(HSA) under normal therapeutic conditions and is therefore known as a drug with 
small volume of distribution and low clearance (Holford and Benet, 1998). 
HSA is comprised of a single polypeptide chain with 585 amino acid residues, 
arranged in three structurally similar ∝-helical domains, namely, domains I, II and 
III. Each domain is further divided into two subdomains, A and B, which include 
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six and four ∝-helices, respectively connected by long ∝-helical chains involving 
residues: 101-124, 289-316 and 487-514. These domains are connected with each 
other through nonhelical segments between 177-200 and 369-392 residues (Carter 
et al., 1989; Carter and He, 1990).  
Interactions of pharmaceutical drugs with serum components play an important 
role in drug delivery. Specific interactions of drugs and their competition for 
binding sites on transport proteins can significantly influence their distribution in 
serum. HSA, being the major transport protein of mammalian blood circulation 
binds a large number of drugs varying in structure. Therefore, information on the 
drug-HSA interaction will give a better understanding of the absorption and 
distribution of a particular drug. Structural studies have shown specific locations 
of the drug binding sites on HSA involving some domains or subdomains of the 
protein (He and Carter, 1992). Thus, many drugs bind to one of the two primary 
binding sites on the protein, known as Sudlow’s sites I and II (Sudlow et al., 
1975).  
Warfarin is known to bind to site I of HSA, which is also known as the warfarin-
azapropazone binding site (Birkett et al., 1980; Fehske et al., 1981; Fehske et al., 
1982). This site is composed of overlapping regions and is responsible for the 
specific binding of warfarin and other drugs such as azapropazone and 
phenylbutazone. Due to its well-characterized interaction to HSA, warfarin is 
often used as a marker ligand for the specific binding to site I on HSA (Sjoholm et 
al., 1979). In other words, warfarin is being employed as a probe to study the 
interactions of other drugs at Sudlow site I on HSA (Oida, 1986; Bertucci et al., 
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1999). The warfarin binding site is a hydrophobic cavity in subdomain IIA, 
formed as a result of packing of all six helices of subdomain IIA (He and Carter, 
1992). Warfarin binding to HSA involves both hydrophobic (dominant) and 
electrostatic interactions. Several hydrophobic residues (Phe-211, Trp-214, Leu-
219, Leu-238, Val-241, Ile-260, Ile-264, Ile-280 and Ala-291) as well as aliphatic 
portions of some polar residues (Arg-218, Arg-222, His-242, Arg-257 and Ser-
287) in the binding pocket offer hydrophobic contacts to the incoming ligand 
(warfarin). On the other hand, Arg-222 and His-242 contribute to electrostatic 
interactions between warfarin and HSA (Petitpas et al., 2001). 
Formation of native, globular and biologically active conformation of a protein is 
the result of protein folding involving both noncovalent and covalent interactions. 
Importance of the globular conformation of a protein for its biological function 
can be reflected by the complete loss of biological activity in presence of 
denaturants (Tanford, 1968). Denaturation usually results in the destruction of the 
protein’s tertiary structure, leading to the change in its ligand binding ability since 
all functions of proteins are displayed by their three-dimensional structures (Dill 
and Shortle, 1991). Alteration in protein’s binding ability due to unfolding 
process as seen in patients with renal or liver disease (Kremer et al., 1988) as well 
as elderly patients (Leslie et al., 1992) can be reflected by the unbound drug 
concentration in plasma. Urea and guanidine hydrochloride are the two common 
chemical denaturants employed for protein denaturation studies. These 
denaturants bind to the peptide groups and weaken internal hydrogen bonds in 
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proteins, and change the surrounding water structure, thus weaken the 
hydrophobic interactions as well (De Aspuru and Zaton, 1993).           
The purpose of this study was to examine the effect of urea on the three-
dimensional structure of HSA as well as on its interaction with warfarin in order 
to correlate the change in drug binding with the protein conformation. In other 
words, we studied the binding of warfarin to both native and altered 
conformations of HSA induced by different urea concentrations using 
fluorescence spectroscopic method due to its great sensitivity.  
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LITERATURE REVIEW 
2.1     GENERAL 
Serum albumin is the most abundant soluble protein constituent of blood plasma 
with a typical concentration of 50g/L (Carter and Ho, 1994). It has been 
categorized as a member of the multigene protein family that includes other 
plasma proteins such as ∝-fetoprotein (AFP) (Deutsh, 1991) and the human group 
specific component (Gc) or vitamin D-binding protein (Cooke and Hadded, 
1989). The name ‘albumin’ evolved from a German word for protein, albumen. 
Originally, it was derived from the Latin word; albus meaning white, based on the 
colour of the part surrounding the yolk of a cooked egg. Furthermore, the ending 
‘–in’ specified a protein from blood plasma. Under normal conditions, albumin 
concentration remains usually very low in other parts of the body in comparison 
to the plasma (Halliwell, 1988). Thus, around 40% of total albumin is present in 
the circulatory plasma (Peters, 1992) while half of the remaining 60% in viscera 
and half in skin and muscle (Rabilloud et al., 1988). Albumin has also been 
identified in amniotic fluid (Bala et al., 1987), semen (Blumsohn et al., 1991), 
milk (Phillippy and McCarthy, 1979) and mammary cysts (Balbin et al., 1991). 
The normal concentration of albumin in human plasma varies between 35 and 
50g/L through transcriptional control of the albumin gene by the anabolic 
hormones, insulin and somatotropin (Hutson et al., 1987; Peters, 1996). Albumin 
plays an important role in the circulatory system for transporting a large number 
of endogenous and exogenous compounds such as drugs, metabolites, fatty acids 
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and metal ions as well as in the regulation of osmotic pressure and fluid 
distribution among various parts of the body (Carter and Ho, 1994).  
It is one of the few proteins commercially available with high purity and low cost. 
These properties in addition to its solubility and lack of prosthetic groups/ 
carbohydrates have made it as the best choice for a model protein in different 
fields including research. Many studies on albumin have been reported in the 
literature, giving details of its different properties including its biological and 
physiological aspects, chemistry, structure, metabolism, genetics and clinical 
applications, etc (Foster, 1960; Rosenoer et al., 1977; Peters, 1985). A book 
entitled “All about Albumin. Biochemistry, Genetics and Medical Application” 
has also been written by Peters (1996) and published by Academic Press Inc., 
New York. 
2.2     PHYSICO-CHEMICAL PROPERTIES OF HSA  
Most of the studies have been performed using albumin purified from bovineor 
human plasma. Table 2.1 summarizes some of the physico-chemical properties of 
human serum albumin (HSA).  A value of 66,438Da has been assigned for 
molecular mass of HSA based on its amino acid composition (Minghetti et al., 
1986). Values of sedimentation coefficient (ܵଶ଴,௪௢ ), diffusion coefficient (ܦଶ଴,௪௢ ) 
and partial specific volume (ݒ̅ଶ) of HSA were measured as 4.6ൈ 10ିଵଷs, 6.1ൈ
10ି଻ܿ݉ଶ/sec and 0.733cc/g respectively (Oncley et al., 1947; Hunter, 1966). The 
intrinsic viscosity [η] and frictional coefficient (f/ ௢݂) for the protein were found as 
4.2cc/g (Hunter, 1966) and 1.28 (Oncley et al., 1947) respectively. HSA was 
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found to possess an overall dimensions of 38ൈ 150Å (Hughes, 1954) with an 
axial ratio of around 3.9:1 (Oncley et al., 1947). It has an isoelectric point of 4.7 
(Longsworth and Jacobsen, 1949) whereas the isoionic point was 5.16 (Hughes, 
1954). HSA contains about 67% ߙ-helix and 10% ߚ-form as reported by Carter 
and Ho (1994). The specific extinction coefficient, ܧଵ௖௠ଵ%  of HSA at 279nm was 
determined as 5.31 (Janatova et al., 1968).  
2.3     STRUCTURE OF HSA  
2.3.1     Amino acid composition  
HSA is known as a simple protein due to the presence of amino acids only and 
lack of any other groups such as carbohydrate or any other non-protein moiety. 
Table 2.2 shows the amino acid composition of HSA. Albumin is characterized by 
the low content of isoleucine, methionine and glycine residues, whereas it has 
high content of leucine, cysteine and charged amino acids such as aspartic acid, 
glutamic acid, lysine and arginine. It is also characterized by the presence of a 
single tryptophan (Trp) residue (Minghetti et al., 1986). Out of 35 cysteine (Cys) 
residues, 34 Cys are involved in the formation of 17 disulfide bonds, leaving only 
one Cys residue free. The high content of ionized residues in albumin (about 185 
ions per molecule at pH 7.0) makes it a molecule with a high total charge leading 
to its greater solubility. 
2.3.2     Primary structure 
HSA contains 585 amino acid residues, arranged in the form of a linear sequence 
in a single polypeptide chain (Brown, 1976; Carter and Ho, 1994). Figure 2.1 
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Table 2.1     Some physico-chemical properties of human serum albumin. 
 Property Value Reference 
 
Molecular mass 
(From amino acid 
composition) 
66,438Da Minghetti et al. (1986) 
Sedimentation coefficient, 
ܵଶ଴,௪௢  
4.6ൈ 10ିଵଷs Oncley et al. (1947) 
Diffusion coefficient, ܦଶ଴,௪௢  6.1ൈ 10ି଻dܿ݉ଶ/s           "             " 
Frictional coefficient, f/ ௢݂ 1.28           "             " 
Partial specific volume, ݒ̅ଶ 0.733ܿ݉ଷ/g Hunter (1966) 
Intrinsic viscosity, [η] 4.2cc/g      "          " 
Overall dimensions 38ൈ150 Å Hughes (1954) 
Axial ratio 3.9:1 Oncley et al. (1947) 
Isoelectric point 4.7 
Longsworth and Jacobsen 
(1949) 
Isoionic point 5.16 Hughes (1954) 
ܧଵ௖௠ଵ%  at 279nm 
Secondary structures 
5.31 
 
Janatova et al. (1968) 
 
			ߙ-helix, % 67 Carter and Ho (1994) 
			ߚ-form, % 
 
10 
 
Carter and Ho (1994) 
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shows the loop-link-loop pattern in the primary structure of HSA, whereas the 
amino acid sequence of HSA, as derived from the cDNA data, is given in Figure 
2.2. Primary structure of HSA is very close to bovine serum albumin (BSA) in its 
disulfide bonding pattern and has 76% sequence homology (Peters, 1985; He and 
Carter, 1992; Carter and Ho, 1994). In all known albumin sequences, about 50% 
of residues are conserved (Carter and Ho, 1994). The 17 disulphide bridges of 
HSA create nine double loops (L1െL9) producing a pattern of three ߙ-helical 
domains, namely, I, II and III as shown in Figure 2.1 (He and Carter, 1992). All 
loops do not have same length, but they are arranged in a triplet fashion of a long-
short-long pattern to make three homologous domains. 
Each domain consists of two longer loops, separated by a shorter loop. Domains I, 
II and III are comprised of residues 1െ195, 196െ383 and 384െ585 respectively 
in the primary sequence of HSA (Carter and Ho, 1994). The average sequence 
homology among these domains is around 18െ25%, being 25%, 21% and 18% 
between domains I and II, II and III and I and III respectively (Brown, 1977). At 
neutral pH, the negative charge distribution in across the surface of the HSA 
molecule is െ9, െ8 and ൅2 for domains I, II and III respectively (Peters, 1996). 
The conformation of disulfide bridges exhibits both gauche-gauche-gauche and 
gauche-gauche-trans conformations and their conformations are changed during 
acid-induced isomerization (Nakamura et al., 1997).  
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         Table 2.2     Amino acid composition of human serum albumin.* 
Amino acid Three-letter 
abbreviation
One-letter 
symbol 
Number of 
residues 
Glycine Gly G 12 
Alanine Ala A 62 
Valine Val V 41 
Leucine Leu L 61 
Isoleucine Ile I 8 
Proline Pro P 24 
Serine Ser S 24 
Threonine Thr T 28 
Aspartic acid Asp D 36 
Asparagine Asn N 17 
Glutamic acid Glu E 62 
Glutamine Gln Q 20 
Histidine His H 16 
Lysine Lys K 59 
Arginine Arg R 24 
Phenylalanine Phe F 31 
Tyrosine Tyr Y 18 
Tryptophan Trp W 1 
Cysteine Cys C 35 
Methionine Met M 6 
Total   585 
 
          * Taken from Minghetti et al. (1986) 
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Figure 2.1  Illustration of the loop-link-loop pattern in the primary structure of 
serum albumin showing different domains and loops (L1-L9) (Taken from Carter 
and Ho, 1994).  
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 1                      10 20 30 40 50 
DAHKSEVAHR FKDLGEENFK ALVLIAFAQY LQQCPFEDHV KLVNEVTEFA 
60 70 80 90 100 
KTCVADESAE NCDKSLHTLF GDKLCTVATL RETYGEMADC CAKQEPERNE 
110 120 130 140 150 
CFLQHKDDNP NLPRLVRPEV DVMCTAFHDN EETFLKKYLY EIARRHPYFY 
160 170 180 190 200 
APELLFFAKR YKAAFTECCQ AADKAACLLP KLDELRDEGK ASSAKQRLKC 
210 220 230 240 250 
ASLQKFGERA FKAWAVARLS QRFPKAEFAE VSKLVTDLTK VHTECCHGDL 
260 270 280 290 300 
LECADDRADL AKYICENQDS ISSKLKECCE KPLLEKSHCI AEVENDEMPA 
310 320 330 340 350 
DLPSLAADFV ESKDVCKNYA EAKDVFLGMF LYEYARRHPD YSVVLLLRLA 
360 370 380 390 400 
KTYETTLEKC CAAADPHECY AKVFDEFKPL VEEPQNLIKQ NCELFKQLGE 
410 420 430 440 450 
YKFQNALLVR YTKKVPQVST PTLVEVSRNL GKVGSKCCKH PEAKRMPCAE 
460 470 480 490 500 
DYLSVVLNQL CVLHEKTPVS DRVTKCCTES LVNRRPCFSA LEVDETYVPK 
510 520 530 540 550 
EFNAETFTFH ADICTLSEKE RQIKKQTALV ELVKHKPKAT KEQLKAVMDD 
560 570 580           585  
FAAFVEKCCK ADDKETCFAE EGKKLVAASQ  AALGL  
 
Figure 2.2  Amino acid sequence of human serum albumin (Taken from 
Minghetti et al., 1986). 
 
 
13 
 
2.3.3     Three-dimensional structure     
The analysis of the three-dimensional (3-D) structure of HSA using X-ray 
diffraction at 3.2 Å resolution shows the involvement of 67% of the total residues 
of crystalline HSA in 28 ߙ-helical regions, whereas the rest of the chain is 
extended peptide chain with a 10% ߚ turn (Carter and Ho, 1994). Figure 2.3 
shows schematic drawing of a heart-shaped HSA molecule, consisting of three 
domains, which are made up of nine loops and 17 disulfide bridges (He and 
Carter, 1992). Each domain is further divided into two sub-domains, namely, A 
and B, which are widely cross-linked by the disulphide bridges. There are 10 
principal helices for the two subdomains, h1െh6 for sub-domain A and h7െh10 
for sub-domain B. The connections between domains IെII and IIെIII in turn are 
made through h10(I)െh1(II) and h10(II)െh1(III) extensions, respectively. 
Various loops, such as L1-L2, L4-L5 and L7-L8 are grouped as subdomains IA, 
IIA and IIIA, respectively whereas loops L3, L6 and L9 form subdomains IB, IIB 
and IIIB respectively. In HSA, the single Trp residue (Trp-214) is located in loop 
L4. 
The stability of overall native 3-D conformation of HSA is maintained by various 
factors such as intra- and inter-domain forces like salt bridges, hydrophobic 
interactions and natural boundaries of helical extensions present between three 
domains. Two primary binding sites in HSA (Site I and II) are characterized by 
the hydrophobic cavities for the binding of various compounds and are located in 
subdomains IIA and IIIA respectively (He and Carter, 1992). 
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Figure 2.3  Schematic drawing of the HSA molecule. Each subdomain is marked 
with a different color (yellow for subdomain Ia; green, Ib; red, IIa; magenta, IIb; 
blue, IIIa and cyan, IIIb). N- and C-termini are marked as N and C, respectively 
(Taken from Sugio et al., 1999). 
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2.4     DENATURATION 
Due to the requirement of the native and globular conformation of a protein for its 
biological function, a number of denaturation studies have been performed on 
serum albumin to understand its folding mechanism. These studies involved the 
use of different denaturants such as temperature, pH, pressure and chemical 
denaturants like urea and guanidine hydrochloride (GdnHCl) (Hayakawa et al., 
1996; Tanaka et al., 1997; Flora et al., 1998; Kosa et al., 1998; Farruggia and 
Pico, 1999; Muzammil et al., 1999; 2000; Tayyab et al., 2000; Gonzalez-Jimenez 
and Cortijo, 2002; Krishnakumar and Panda, 2002; Santra et al., 2004; Ahmad et 
al., 2005; Sen et al., 2008; Rownicka-Zubik et al., 2009). Denaturation of a 
protein usually results in the transformation of its tertiary structure into primary 
structure, which is capable of regaining native structure of the protein after 
removal of the denaturants by slow oxidation of its thiol groups to disulfide bonds 
(Anfinsen, 1973; Johanson et al., 1977; Wichman et al., 1977; Chavez and 
Benjamin, 1978).  
Denaturation of serum albumin has been studied using different probes such as 
intrinsic fluorescence, circular dichroism (CD) spectral signal, 1-
anilinonaphthalene-8-sulfonic acid (ANS) fluorescence, ultraviolet (UV) 
difference spectral signal, reduced viscosity etc (Khan et al., 1987; Tayyab et al., 
1995; Pico, 1995; Farruggia et al., 1997; Muzammil et al., 2000; Gonzalez-
Jimennez and Cortijo, 2002; Kumar et al., 2005). In HSA, the presence of a single 
Cys residue in domain I, a single Trp residue in domain II and a number of 
reactive Tyr residues in domain III support the possibility to study the unfolding 
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and folding pathways of each domain (Brown, 1977; Means and Wu, 1979; 
Fehske et al., 1980; Flora et al., 1998; Krishnakumar and Panda, 2002). Both 
chemical denaturants (urea and GdnHCl) denature proteins through their binding 
to the peptide groups and weakening the internal hydrogen bonds of the protein as 
well as changing the surrounding water structure, thus weakening the 
hydrophobic interactions as well (De Aspuru and Zaton, 1993). Earlier studies on 
urea denaturation of HSA using intrinsic fluorescence measurements upon 
excitation at 280nm have shown a two-step, three-state transition with the 
presence of a stable intermediate around 4.8െ5.2M urea whereas the transition 
displayed a single-step, two-state process when the urea denaturation was 
monitored by Trp fluorescence (Khan et al., 1987; Ahmad and Qasim, 1995; 
Muzammil et al., 2000; Tayyab et al., 2000; 2002). Urea denaturation of serum 
albumin has been suggested to start with the unfolding of domain III followed by 
the unfolding of the remaining two domains (Tanaka et al., 1993; Ahmad and 
Qasim, 1995). Various domain specific ligands such as drugs and non-drug 
ligands have been widely used to study urea denaturation of serum albumin 
(Tayyab et al., 2000; Santra et al., 2004; Rownicka-Zubik et al., 2009). GdnHCl 
denaturation of serum albumin has shown a single-step, two-state transition 
(Farruggia and Pico, 1999; Kosa et al., 1998; Kamal et al., 2004).  
2.5    LIGAND BINDING 
The main function of HSA besides controlling the osmotic pressure, is the 
transport of a wide variety of endogenous and exogenous ligands, both anionic 
and cationic in nature (Figure 2.4). These include fatty acids, hormones, 
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metabolites, metal ions, amino acids, steroids, dyes, drugs etc (Hultmark et al., 
1975; Sollene et al., 1981; Spector, 1986; Watanabe et al., 1991; Sadler et al., 
1994; Peters, 1996). These ligands (both hydrophilic and hydrophobic in nature) 
bind to serum albumin with a binding constant in the range, 10ସ െ 10଼Mିଵ 
(Carter and Ho, 1994) at multiple sites in a reversible manner (Curry et al., 1998; 
Bhattacharya et al., 2000; Petitpas et al., 2001; Wardell et al., 2002; Petitpas et 
al., 2003; Zunszain et al., 2003). Most of the ligand binding studies have been 
made using equilibrium dialysis or various spectroscopic methods and the binding 
data are generally analyzed by Scatchard method (Scatchard, 1949).   
The ligand binding sites on serum albumin have been classified into two 
categories, site I and site II, which are located in subdomains IIA and IIIA 
respectively (Sudlow et al., 1975). According to the Sudlow’s nomenclature, site I 
has been characterized as a binding site for large ligands with a negative charge 
such as dicarboxylic acids and/or bulky heterocyclic molecules, whereas site II 
has been identified by the binding of aromatic carboxylic acids like non-steroidal 
anti-inflammatory drugs. Site I in comparison to the site II is smaller or narrower 
due to the binding of small ligands and seems to be less flexible (Kragh-Hansen, 
1983; 1985; 1988; Yamasaki et al., 1996). 
Crystal structure of the subdomains containing the binding sites has shown the 
presence of hydrophobic side chains at the inside wall of pocket IIA whereas six 
positively charged residues (Arg 257, Arg 222, Lys 199, His 242, Arg 218 and 
Lys 195) are located at the entrance of the pocket. Similarly, IIIA pocket is also  
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Figure 2.4  Summary of the ligand binding capacity of HSA as defined by 
crystallographic studies. Ligands are depicted in space filling representation; 
oxygen atoms are coloured red; all other atoms in fatty acids (myristic acid), other 
endogenous ligands (hemin, thyroxin) and drugs are coloured dark grey, light 
grey and orange, respectively (Taken from Ghuman et al., 2005). 
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lined by hydrophobic side chains and the double disulfide bridges of helix 
IIIAെh3. Although, in both binding pockets of IIA and IIIA, the charge 
distribution is mostly similar but the sites still have specialized selectivity (Carter 
and Ho, 1994). Furthermore, the two subdomains have an asymmetric 
distribution, characterized by a hydrophobic surface to one side and a basic or 
positively charged surface on the other side (Carter and Ho, 1994).  
2.5.1     Drug binding 
HSA plays a central role in both efficiency and rate of drug delivery due to its 
drug binding properties. Protein binding not only helps in increasing the solubility 
of less polar compounds but also makes their distribution easier throughout the 
body. Therefore, such binding studies have become an important research field in 
chemistry, life science and clinical medicine. Many commonly used drugs such as 
phenylbutazone, indomethacin, aspirin, carbenicillin, warfarin, diazepam, 
ibuprofen etc bind to HSA, usually at one of two primary binding sites (Hultmark 
et al., 1975; Sudlow et al., 1975; He and Carter, 1992; Kosa et al., 1997; 
Rukhadze et al., 2001; Kim and Wainer, 2008; Bojko et al., 2008; Thoppil et al., 
2008). Competitive binding experiments have been used to investigate the binding 
site selectivity (He and Carter, 1992; Bhattacharya et al., 2000; Mao et al., 2001; 
Petitpas et al., 2001). For example, marker ligands for sites I and II of serum 
albumin have commonly been employed in competition experiments in order to 
identify the binding locus of a variety of compounds (Sudlow et al., 1975; Fehske 
et al., 1981; Kragh-Hansen, 1988; Yamasaki et al., 1996). The interaction 
between drug and albumin has long been of interest in pharmaceutical industry 
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due to its importance in pharmacokinetics and pharmacodynamics of drugs 
(Hodgson, 2001; Rich et al., 2001; Buchholz et al., 2002; Kratochwil et al., 2002; 
Valko et al., 2003). 
2.5.2     Warfarin binding to HSA 
Warfarin [3-(ߙ-acetonylbenzyl)-4-hydroxycoumarin], an anticoagulant drug, has 
been widely used in the treatment of some illnesses such as venous thrombosis 
and pulmonary embolism (Bell and Simon, 1982; Peterson et al., 1989; Peterson 
and Kwaan, 1986), as well as in the prevention of prosthetic heart valve 
thromboembolism (Mok et al., 1985). It acts by inhibiting the production of 
vitamin K-dependant clotting factors including, factors II, VII, IX and X 
(O’Reilly, 1976). The structure of warfarin is usually drawn as an open chain 
structure but it is generally believed to exist as a cyclic hemiketal in solution 
(Giannini et al., 1974) and this form is the same as that observed in warfarin 
crystals (Valente et al., 1975). Figure 2.5 shows the structure of warfarin. 
Under normal therapeutic conditions, warfarin is 99% bound to the protein (HSA) 
in circulation (Holford and Benet, 1998). Warfarin binding to HSA has been 
extensively studied and the binding site of warfarin on HSA is known as the 
warfarin-azapropazone binding area or site I of the HSA molecule (Birkett et al., 
1980; Fehske et al., 1981; Fehske et al., 1982). This site is composed of 
overlapping regions for the specific binding of warfarin and other similar drugs 
such as coumarinic anticoagulants (Zaton et al., 1995), loop diuretics (Takamura 
et al., 1996), azapropazone, phenylbutazone and iodipamide (Yamasaki et al.,  
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Figure 2.5   Chemical structure of warfarin [3-(ߙ-acetonylbenzyl)-4-
hydroxycoumarin].  
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1996). Warfarin binds to HSA with an apparent binding constant (ܭ௕ሻ in the 
range of 2.5െ3.3	ൈ 10ହMିଵ for the primary binding site (Sundlow et al., 1975; 
Kragh-Hansen, 1981; Pinkerton and Koeplinger, 1990). Due to its specific 
binding to site I on HSA, warfarin is often used as a competing agent or a marker 
ligand for investigating the specific binding of other drugs molecules to site I on 
HSA (Sjoholm et al., 1979; Oida, 1986; Bertucci et al., 1999).  
Sudlow’s site I, the binding site of warfarin, has been identified as a 
conformationally adaptable region with up to three subcompartments and is 
formed as a result of packing of all six helices of subdomain IIA (Fehske et al., 
1981; Kragh-Hansen, 1988; He and Carter, 1992; Yamasaki et al., 1996). 
Warfarin binding to HSA involves both hydrophobic (dominant) and electrostatic 
interactions. Several hydrophobic residues (Phe-211, Trp-214, Leu-219, Leu-238, 
Val-241, Ile-260, Ile-264, Ile-280 and Ala-291) as well as aliphatic portions of 
some polar residues (Arg-218, Arg-222, His-242, Arg-257 and Ser-287) in the 
binding pocket offer hydrophobic contacts to the incoming ligand (warfarin), 
whereas Arg-222 and His-242 contribute to electrostatic interactions between 
warfarin and HSA (Petitpas et al., 2001).  
It is of interest to know how warfarin or similar other drugs are transported by 
HSA with altered tertiary structure and to classify the drugs that protect HSA 
against denaturation. Furthermore, for effective therapeutic monitoring of the 
drug, it is necessary to know the binding parameters of drug-protein interaction 
during HSA destabilization as changes in the binding characteristics reflected in 
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the unbound drug concentration. In clinical situations, where plasma protein 
binding may be altered, total drug concentrations must be interpreted with 
caution. Although, a number of reports are available in the literature on the 
binding of warfarin to HSA but no attempt has been made to study the effect of 
chemical denaturants on the binding of warfarin to HSA. In view of the above, it 
would be of interest to study warfarin binding to HSA in presence of different 
urea concentrations. With this aim in mind, the objectives set for this study were 
as follows: 
1. To study urea denaturation of HSA using fluorescence spectroscopy 
and  
2. To compare the warfarin binding to HSA in the absence and presence of 
different urea concentrations. 
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MATERIALS AND METHODS 
 
3.1          MATERIALS 
Human serum albumin (HSA), essentially fatty acid free (Lot 104K7636), 
warfarin (minimum 98%) (Lot 104K1261), ultra pure urea (Lot 127K01061) and 
standard buffers of pH 7 and 4 were purchased from Sigma-Aldrich Inc., USA. 
Disodium hydrogen phosphate, sodium dihydrogen phosphate and sodium 
hydroxide were obtained from Systerm, Malaysia.  
Whatman filter papers (No.1) were supplied by Whatman International Ltd., 
England. Parafilm ‘M’ was the product of American National Can Company, 
USA. 
All glass distilled water was used throughout these studies. All experiments were 
performed at room temperature (~25oC). 
3.2.          METHODS 
3.2.1. pH measurements 
pH measurements were made on a Mettler-Toledo pH meter, model Delta 320 
using a BNC’s combined electrode, type HA405-K2/120 including glass and 
reference electrodes in a single entity. The least count of the pH meter was 0.01 
pH unit. The pH meter was calibrated at room temperature with both standard 
buffers of pH 7 and 4. 
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3.2.2. Analytical methods 
Protein concentration was determined spectrophotometrically on a Shimadzu 
double beam Spectrophotometer, model UV-2450, using a specific extinction 
coefficient, ܧଶ଻ଽ௡௠ଵ%  of HSA as 5.31 (Janatova et al., 1968). 
The concentration of stock urea solution was determined from the data of Warren 
and Gordon (1966), as described by Pace et al. (1989). 
3.2.3. Absorption measurements 
Light absorption measurements in the ultraviolet range were carried out at 25oC 
on a Shimadzu double beam Spectrophotometer, model UV-2450 using quartz 
cuvettes of 1cm path length. 
3.2.4. Fluorescence measurements 
Fluorescence measurements were performed on a Hitachi Fluorescence 
Spectrophotometer, model F-2500. Fluorescence spectra were recorded at a 
protein concentration of 1/ 1.8µM with a 1-cm path length cell. The excitation and 
emission slits were set at 10nm each. Intrinsic fluorescence was measured by 
exciting the protein solution at either 280 or 295nm and emission spectra were 
recorded in the wavelength range, 300-400nm. 
3.2.5. Denaturation experiments 
Urea denaturation experiments were performed in the same way as described 
earlier (Tayyab et al., 2000). Solutions for denaturation experiments were 
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prepared in 0.06M sodium phosphate buffer, pH 7.4. The stock protein solution 
(18µM) was prepared by dissolving 29.3mg of HSA in 25ml of the same buffer. 
To 0.5ml of stock protein solution, different volumes of the buffer were added 
first followed by the addition of increasing volumes of stock denaturant solution 
(10M urea) to get the desired concentration of the denaturant. The final solution 
mixture (5ml) was incubated for 12 hours at room temperature and fluorescence 
spectra were recorded in the wavelength range, 300-400nm upon excitation at 
both 280 and 295nm. Denaturation experiments were performed at least 2-3 times 
and results were found reproducible.  
Denaturation experiments were also performed following the above method but 
with 60 minutes incubation time.  
3.2.6. Drug binding studies 
The interaction of warfarin with HSA was studied using fluorescence 
spectroscopy both in the absence and presence of different urea concentrations. 
All experiments were carried out in 0.06M sodium phosphate buffer, pH 7.4 and 
at 25oC.  
Stock drug (400µM) and protein (18µM) solutions were prepared separately by 
dissolving 3.1mg of warfarin and 29.3mg of HSA in 25ml of buffer. Increasing 
volumes (3-500µl) of stock drug solution were added to a fixed volume 
(280µl/500µl) of stock protein solution, taken in different tubes and incubated for 
15 minutes at room temperature. It was followed by the addition of a fixed 
volume of the stock denaturant solution. The final volume in each tube was made 
27 
 
to 5ml with buffer, if needed and the solution mixtures were incubated for 
additional 60 minutes at room temperature. Fluorescence spectra were recorded 
upon excitation at both 280 and 295nm. Same protocol was used in different 
experiments involving different urea concentrations.  
3.2.7. Data analysis 
Drug-binding data were analyzed using Stern-Volmer equation (Eftink and 
Ghiron, 1982). 
   ܨ଴ ܨ ൌ 1 ൅ ܭ௦௩⁄ ሾܳሿ            
where ܨ଴ and ܨ are the fluorescence intensities at an appropriate wavelength in 
the absence and presence of drug, respectively, ܭ௦௩ is the Stern-Volmer constant, 
and [Q] is the molar concentration of the drug. 
Binding constant of drug-protein interaction was determined using following 
equation (Min et al., 2004): 
log	 ܨ଴ െ ܨܨ ൌ logܭ௕ ൅ n logሾܳሿ 
where Q is the concentration of the drug, ܭ௕	 is the binding constant, n is the 
number of binding sites and ܨ଴ and F are the values of fluorescence intensity in 
the absence and presence of drug respectively. A plot of log [(ܨ଴ െ ܨሻ/
ܨሿ	versus	log	ሾܳሿ, gave a straight line with a slope of n and y-axis intercept of log 
ܭ௕.  
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RESULTS AND DISCUSSION 
4.1. EFFECT OF UREA ON THE FLUORESCENCE SPECTRUM OF HSA 
4.1.1 Using excitation wavelength of 280nm 
Figure 4.1 shows intrinsic fluorescence spectra of HSA (1.8µM) in the absence 
and presence of increasing urea concentrations (0.5-8.5M) with an incubation 
time of 12 hours when excited at 280nm. The fluorescence spectrum of native 
HSA was characterized by the presence of an emission maximum around 339nm. 
Addition of increasing concentrations of urea to HSA solution produced a 
significant decrease in the fluorescence intensity and shift in the emission 
maximum. Decrease in the fluorescence intensity was smaller in the beginning (0-
3M), followed by a pronounced change in the middle range (3.5-6.5M) and 
smaller variations at higher (6.5-8.5M) urea concentrations. These changes in the 
fluorescence intensity can be clearly seen from Figure 4.2A where values of the 
fluorescence intensity at 339nm were plotted against different urea 
concentrations. The urea transition curve showed a two-step, three-state transition. 
The transition started at 3M urea and completed around 6.5M urea with the 
accumulation of an intermediate in the range of 5.2-5.6M urea concentrations. 
These results were similar to earlier reports on urea denaturation of HSA 
(Muzammil et al., 2000; Ahmad et al., 2004). In addition to the change in the 
fluorescence intensity, emission maximum also showed variation with increasing 
urea concentrations (Figure 4.2B). The emission maximum was blue shifted from  
 
29 
 
  
Figure 4.1  Fluorescence spectra of HSA (1.8µM) in the absence and presence of 
increasing urea concentrations in 0.06M sodium phosphate buffer, pH 7.0 at 25Ԩ 
incubated for 12 hours, upon excitation at 280nm. Urea concentrations from top to 
bottom (1-22) were: 2.0, 3.0, 1.5, 2.5, 1.0, 0.5, 0.0, 3.5, 4.0, 4.5, 4.6, 4.8, 5.0, 5.2, 
5.4, 5.5, 6.0, 8.5, 6.5, 7.5, 7.0 and 8.0M respectively. 
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Figure 4.2  Urea denaturation curves of HSA as studied by plotting (A) 
fluorescence intensity at 339nm upon excitation at 280nm and (B) emission 
maximum against urea concentration. Data of fluorescence intensity and emission 
maximum at different urea concentrations were obtained from Figure 4.1. 
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339 to 335nm within urea concentration range, 2-5M, remained constant till 5.5M 
urea and then showed a red shift of 8.0nm till 8.0M and became constant 
thereafter. 
Decrease in the fluorescence intensity observed within urea concentration range, 
3.5-6.5M, can be ascribed to the change in the microenvironment around 
tryptophan (Trp) and tyrosine (Tyr) residues of HSA from nonpolar to polar 
(Rownicka et al., 2006). These results were supported by the significant red shift 
observed with increasing urea concentrations (Figure 4.2B). Both decrease in the 
fluorescence intensity and red shift in the emission maximum were suggestive of 
protein denaturation. Furthermore, the fluorescence spectrum of HSA showed two 
emission maxima at 307 and 343nm at higher (൐6M) urea concentrations (Figure 
4.1). Presence of emission maximum at 307nm can account for Tyr fluorescence 
whereas emission maximum at 343nm corresponds to Trp fluorescence (Ahmad et 
al., 2005; Rownicka et al., 2006; Qu et al., 2009). HSA contains 18 Tyr residues, 
distributed in all three domains and single Trp residue, localized in subdomain 
IIA (Minghetti et al., 1986). Tyrosine fluorescence remains quenched in the 
native three-dimensional structure of the protein due to the presence of Trp 
residue (Rownicka-zubik et al., 2009). Denaturation at higher urea concentrations 
led to the separation of Tyr and Trp residues, thus leading to the appearance of 
two maxima in the fluorescence spectrum of HSA. Origin of a new peak at 307nm 
can also account for the smaller decrease in emission maximum observed at lower 
urea concentrations (Figure 4.2B). 
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In order to study the effect of 60 minutes incubation time on the urea denaturation 
characteristics of HSA, denaturation experiments were also performed using 60 
minutes incubation time with urea. Figure 4.3A and B show urea denaturation 
curves of HSA when monitored by fluorescence intensity at emission maximum 
(338nm) and emission maximum respectively. As can be seen from the figure, 
transition curves were found to be similar to those obtained with 12 hours 
incubation (Figure 4.2A and B). 
4.1.2 Using excitation wavelength of 295nm 
Urea denaturation studies of HSA were also made using fluorescence 
spectroscopy upon excitation at 295nm (to excite Trp residues only) with an 
incubation time of 12 hours. Figure 4.4 shows fluorescence spectra of HSA 
(1.8µM) both in the absence and presence of increasing (0-8M) urea 
concentrations when excited at 295nm. Fluorescence spectrum of HSA showed an 
emission maximum at 343nm. Addition of increasing urea concentrations resulted 
in quenching of Trp fluorescence as well as red shift in the emission maximum. 
These changes were more visible in Figure 4.5A and B where fluorescence 
intensity at 338nm and emission maximum respectively have been plotted against 
urea concentrations. However, these effects were smaller both at lower (0-3M) 
and higher (6-8M) urea concentrations and became more pronounced in the 
middle range, 3-6M, of urea concentrations (Figure 4.5A). Urea denaturation of 
HSA showed a single-step, two-state transition when monitored by Trp 
fluorescence. The transition was characterized by the start- and end-points at 3M 
and 6M urea respectively. Similarly, urea denaturation curve probed by emission  
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Figure 4.3  Urea denaturation curves of HSA (1.0µM) as studied by plotting (A) 
fluorescence intensity at 338nm upon excitation at 280nm and (B) emission 
maximum against urea concentration. Incubation time with urea was kept as       
60 minutes.  
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Figure 4.4 Fluorescence spectra of HSA (1.8µM) in the absence and presence of 
increasing urea concentrations in 0.06M sodium phosphate buffer, pH 7.0 at 25Ԩ 
incubated for 12 hours, upon excitation at 295nm. Urea concentrations from top to 
bottom (1-17) were: 1.5, 0.5, 3.0, 2.0, 1.0, 3.5, 0.0, 4.0, 4.6, 4.8, 5.2, 5.5, 6.5, 7.0, 
6.0, 8.0 and 7.5M respectively. 
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Figure 4.5  Urea denaturation curves of HSA as studied by plotting (A) 
fluorescence intensity at 343nm upon excitation at 295nm and (B) emission 
maximum against urea concentration. Data of fluorescence intensity and emission 
maximum at different urea concentrations were obtained from Figure 4.4.  
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maximum also showed a single-step transition starting at 5M urea and reaching to 
completion at 7.5M urea (Figure 4.5B). Use of different probes may account for 
the observed differences in the start- and end-points of transitions. Since HSA 
contains single Trp residue, located at 214 position in the primary sequence 
(domain II), urea denaturation of HSA monitored by Trp fluorescence would 
account for the denaturation of the concerned domain only and thus resulted in a 
single-step transition as shown in Figure 4.5. Contrary to it, excitation at 280nm 
was responsible to excite both Tyr and Trp residues of HSA. Since Tyr residues 
are scattered throughout the three domains of HSA molecule, probing urea 
denaturation of HSA with intrinsic fluorescence would give denaturation details 
of all three domains of HSA. That is why the urea denaturation of HSA showed 
two-step transition when probed by intrinsic fluorescence. Decreasing the 
incubation time from 12 hours to 60 minutes did not affect the transition curves to 
a significant extent (Figure 4.6). 
4.2. WARFARIN-HSA INTERACTION 
4.2.1 Warfarin binding to native HSA 
Intrinsic fluorescence spectra of HSA (1µM) both in the absence and presence of 
increasing warfarin concentrations (1-40µM) upon excitation at 280nm are shown 
in Figure 4.7. As can be seen from the figure, native HSA produced the 
fluorescence spectrum in the wavelength range, 300-400nm with an emission 
maximum at 338nm. Appearance of an emission maximum at 338nm was 
indicative of the presence of Trp residue in HSA (Muzammil et al., 2000; Ahmad 
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Figure 4.6  Urea denaturation curves of HSA (1.0µM) as studied by plotting (A) 
fluorescence intensity at 342nm upon excitation at 295nm and (B) emission 
maximum against urea concentration. Incubation time with urea was kept as       
60 minutes. 
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Figure 4.7  Fluorescence spectra of HSA (1.0µM) in the absence and presence of 
increasing warfarin concentrations in 0.06M sodium phosphate buffer, pH 7.0 at 
25Ԩ incubated for 60 minutes, upon excitation at 280nm. Warfarin 
concentrations from top to bottom (1-14) were: 0.0, 1.0, 1.3, 1.6, 2.0, 2.5, 3.0, 4.0, 
5.0, 10.0, 15.0, 20.0, 30.0 and 40.0µM respectively. 
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et al., 2005). Both decrease in the fluorescence intensity and red shift in the 
emission maximum were observed in the fluorescence spectrum of HSA in 
presence of increasing warfarin concentrations (Figure 4.7). These effects were 
more pronounced at lower (0-5µM) drug concentrations and sloped off at higher 
(10-40µM) drug concentrations. This can be clearly seen from Figure 4.8A and B 
where relative fluorescence intensity at 338nm (obtained by taking the 
fluorescence intensity of native HSA at 338nm, in the absence of drug as 100) and 
emission maximum respectively were plotted against drug concentration. About 
45% quenching in the fluorescence intensity was observed up to a warfarin/ HSA 
molar ratio of 5:1. Further increase in the drug concentration from 5 to 40µM led 
to only 35% quenching in the fluorescence intensity, being 80% at 40µM drug 
concentration (Figure 4.8A). 
Similarly, red shift in the emission maximum was more marked (22nm) at 5µM 
drug concentration and became smaller at higher drug concentrations. The value 
of emission maximum reached to 376nm at 20µM drug concentration and 
remained the same (within experimental error) up to 40µM drug concentration 
(Figure 4.8B). Both decrease in the fluorescence intensity and red shift in the 
emission maximum of HSA with increasing warfarin concentrations were 
indicative of warfarin binding to HSA. Binding of warfarin to HSA has been well 
studied using different techniques including fluorescence spectroscopy and our 
results were found to be in agreement to those published earlier (Parikh et al., 2000; 
Sulkowska, 2002; Sulkowska et al., 2003). Linear decrease in the fluorescence 
intensity at lower drug concentrations and saturation at higher drug concentrations  
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Figure 4.8  Plots showing change in the relative fluorescence intensity at 338nm 
upon excitation at 280nm (A) and the emission maximum (B) of HSA against 
warfarin concentration. Data of the relative fluorescence intensity and the 
emission maximum at different warfarin concentrations were obtained from 
Figure 4.7.  
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are typical for specific ligand binding to proteins (Tayyab et al., 2000; Ahmad et 
al., 2004).                       
Warfarin binding to HSA was also studied using Trp fluorescence upon excitation 
at 295nm and results are shown in Figure 4.9. The fluorescence spectrum of 
native HSA was characterized by the presence of an emission maximum at 342nm 
which was in line with previous reports (Muzammil et al., 2000; Ahmad et al., 
2004). A comparison of the emission maximum of free Trp in buffer (354nm) 
(Pajot, 1976), with that (342nm) obtained with HSA suggested the internalization 
of Trp in the hydrophobic interior of the protein (Pajot, 1976; Moller and 
Denicola, 2002). Addition of increasing warfarin concentrations to the HSA 
solution led to a significant decrease in the fluorescence intensity and red shift in 
the emission maximum. These results on the change in the fluorescence intensity 
and emission maximum with increasing warfarin concentrations (Figure 4.10A 
and B) were found to be similar to those observed upon excitation at 280nm 
(Figure 4.8A and B). The extent of fluorescence quenching and red shift at 5µM 
drug concentration were found as 49% and 31nm respectively and followed the 
linear pattern in the beginning (Figure 4.10A and B). Similarly, at 40µM drug 
concentration, about 79% quenching of Trp fluorescence and 39nm red shift in 
the emission maximum (Figure 4.10A and B) were observed against 80% 
quenching and 37nm red shift (Figure 4.8A and B) noted upon excitation at 
280nm.  
In view of the similar extent of fluorescence quenching observed in the presence 
of warfarin, upon excitation at 280 and 295nm (Figure 4.8A and 10A), it seems  
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Figure 4.9  Fluorescence spectra of HSA (1.0µM) in the absence and presence of 
increasing warfarin concentrations in 0.06M sodium phosphate buffer, pH 7.0 at 
25Ԩ incubated for 60 minutes, upon excitation at 295nm. Warfarin 
concentrations from top to bottom (1-16) were: 0.0, 0.24, 0.75, 1.0, 1.3, 1.6, 2.0, 
2.5, 3.0, 3.5, 5.0, 10.0, 15.0, 20.0, 30.0 and 40.0µM respectively. 
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Figure 4.10  Plots showing change in the relative fluorescence intensity at 342nm 
upon excitation at 295nm (A) and the emission maximum (B) of HSA against 
warfarin concentration. Data of the relative fluorescence intensity and the 
emission maximum at different warfarin concentrations were obtained from 
Figure 4.9.  
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likely that both fluorophores, Trp and Tyr are involved in the drug binding to 
HSA. The quenching of HSA fluorescence can be explained by the energy 
transfer from the fluorophores to the drug molecule in its ground state. Free 
warfarin absorbs in the ultraviolet range with an absorption maximum around 
306nm (Corn and Berberich, 1967). The possibility of energy transfer is more if 
the emission spectrum of HSA (donor) overlaps the absorption spectrum of the 
drug (acceptor) (Valeur, 2002). This condition is met in warfarin-HSA system as 
there is significant overlap between absorption spectrum of warfarin and emission 
spectrum of HSA (Figure omitted for brevity). Furthermore, increase in the 
polarity of the microenvironment around Trp and Tyr residues was also reflected 
by the decrease in the fluorescence intensity and red shift in the emission 
maximum of HSA in the presence of warfarin. The fluorescence quenching of Trp 
residue upon excitation at 295nm suggested the location of warfarin binding site 
close to Trp-214 in subdomain IIA of HSA (Tanaka et al., 1997; Rownicka-Zubik 
et al., 2009). Since drug site I, available in subdomain IIA of HSA contains a 
hydrophobic pocket surrounded by polar clusters (Ghuman et al., 2005), warfarin 
binding to this site might have brought a conformational change leading to 
increased polarity around Trp-214. In class B proteins, Trp residue(s) is(are) 
solely responsible for fluorescence even in the presence of a higher number of Tyr 
residues due to quenching of Tyr fluorescence by Trp and/or energy transfer from 
Tyr to Trp in the native structure of a protein where these residues are closely 
located (Weber, 1960). 
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4.2.2 Warfarin binding to HSA in the presence of urea    
Interaction of warfarin with HSA was also studied in the presence of different 
urea concentrations i.e.: 3.0, 3.5, 4.0, 4.5, 5.3, 6.5 and 8.0M using fluorescence 
spectroscopy. Titration of a constant amount of HSA (1/1.8µM) was performed 
with increasing warfarin concentrations (0.5-40µM) in the presence of fixed urea 
concentration and the resulting fluorescence spectra are shown in Figures 4.11, 
4.13, 4.15, 4.17, 4.19, 4.21 and 4.23 upon excitation at 280nm. Fluorescence 
spectra obtained in the presence of different urea concentrations were found to be 
qualitatively similar to that observed in the absence of urea (Figure 4.7) in terms 
of both decrease in the fluorescence intensity and red shift in the emission 
maximum. However, significant differences in the extent of fluorescence 
quenching as well as red shift in the emission maximum were noticed with 
different urea concentrations. This can be more clearly seen from the plots of 
relative fluorescence intensity and emission maximum against warfarin 
concentration as shown in Figures 4.12, 4.14, 4.16, 4.18, 4.20, 4.22 and 4.24. A 
comparison of these plots obtained at different urea concentrations showed a 
significant decrease both in the extent of fluorescence quenching (Figure 4.25A) 
and red shift in the emission maximum (Figure 4.26A) with the increase in urea 
concentration.  
The pattern of fluorescence quenching with increasing warfarin concentrations 
remained the same at lower urea concentrations, showing marked decrease in the 
fluorescence intensity at lower drug concentrations and smaller decrease at higher  
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Figure 4.11  Fluorescence spectra of HSA (1.0µM) in the absence and presence of 
increasing warfarin concentrations but with 3.0M urea in 0.06M sodium 
phosphate buffer, pH 7.0 at 25Ԩ incubated for 60 minutes, upon excitation at 
280nm. Warfarin concentrations from top to bottom (1-12) were: 0.0, 0.75, 1.0, 
1.3, 1.6, 2.5, 3.5, 10.0, 15.0, 20.0, 30.0 and 40.0µM respectively. 
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Figure 4.12  Plots showing change in the relative fluorescence intensity at 337nm 
upon excitation at 280nm (A) and the emission maximum (B) of HSA in 3.0M 
urea against warfarin concentration. Data of the relative fluorescence intensity 
and the emission maximum at different warfarin concentrations were obtained 
from Figure 4.11. 
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Figure 4.13  Fluorescence spectra of HSA (1.0µM) in the absence and presence of 
increasing warfarin concentrations but with 3.5M urea in 0.06M sodium 
phosphate buffer, pH 7.0 at 25Ԩ incubated for 60 minutes, upon excitation at 
280nm. Warfarin concentrations from top to bottom (1-14) were: 0.0, 2.0, 2.5, 
3.0, 3.5, 4.0, 5.0, 10.0, 15.0, 20.0, 30.0 and 40.0µM respectively. 
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Figure 4.14  Plots showing change in the relative fluorescence intensity at 335nm 
upon excitation at 280nm (A) and the emission maximum (B) of HSA in 3.5M 
urea against warfarin concentration. Data of the relative fluorescence intensity 
and the emission maximum at different warfarin concentrations were obtained 
from Figure 4.13. 
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Figure 4.15  Fluorescence spectra of HSA (1.8µM) in the absence and presence of 
increasing warfarin concentrations but with 4.0M urea in 0.06M sodium 
phosphate buffer, pH 7.0 at 25Ԩ incubated for 60 minutes, upon excitation at 
280nm. Warfarin concentrations from top to bottom (1-15) were: 0.0, 0.75, 1.0, 
1.3, 1.6, 2.0, 3.5, 4.0, 5.0, 10.0, 15.0, 20.0, 30.0 and 40.0µM respectively. 
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Figure 4.16  Plots showing change in the relative fluorescence intensity at 336nm 
upon excitation at 280nm (A) and the emission maximum (B) of HSA in 4.0M 
urea against warfarin concentration. Data of the relative fluorescence intensity 
and the emission maximum at different warfarin concentrations were obtained 
from Figure 4.15. 
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Figure 4.17  Fluorescence spectra of HSA (1.0µM) in the absence and presence of 
increasing warfarin concentrations but with 4.5M urea in 0.06M sodium 
phosphate buffer, pH 7.0 at 25Ԩ incubated for 60 minutes, upon excitation at 
280nm. Warfarin concentrations from top to bottom (1-14) were: 0.0, 0.5, 0.75, 
1.0, 1.3, 1.6, 2.0, 3.0, 3.5, 10.0, 15.0, 20.0, 30.0 and 40.0µM respectively. 
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Figure 4.18  Plots showing change in the relative fluorescence intensity at 336nm 
upon excitation at 280nm (A) and the emission maximum (B) of HSA in 4.5M 
urea against warfarin concentration. Data of the relative fluorescence intensity 
and the emission maximum at different warfarin concentrations were obtained 
from Figure 4.17. 
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Figure 4.19  Fluorescence spectra of HSA (1.0µM) in the absence and presence of 
increasing warfarin concentrations but with 5.3M urea in 0.06M sodium 
phosphate buffer, pH 7.0 at 25Ԩ incubated for 60 minutes, upon excitation at 
280nm. Warfarin concentrations from top to bottom (1-13) were: 0.0, 1.0, 1.3, 
1.6, 3.0, 4.0, 5.0, 10.0, 15.0, 20.0, 30.0 and 40.0µM respectively. 
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Figure 4.20  Plots showing change in the relative fluorescence intensity at 335nm 
upon excitation at 280nm (A) and the emission maximum (B) of HSA in 5.3M 
urea against warfarin concentration. Data of the relative fluorescence intensity 
and the emission maximum at different warfarin concentrations were obtained 
from Figure 4.19. 
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Figure 4.21  Fluorescence spectra of HSA (1.0µM) in the absence and presence of 
increasing warfarin concentrations but with 6.5M urea in 0.06M sodium 
phosphate buffer, pH 7.0 at 25Ԩ incubated for 60 minutes, upon excitation at 
280nm. Warfarin concentrations from top to bottom (1-12) were: 0.0, 0.5, 1.6, 
2.5, 3.5, 4.0, 5.0, 10.0, 15.0, 20.0, 30.0 and 40.0µM respectively. 
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Figure 4.22  Plots showing change in the relative fluorescence intensity at 340nm 
upon excitation at 280nm (A) and the emission maximum (B) of HSA in 6.5M 
urea against warfarin concentration. Data of the relative fluorescence intensity 
and the emission maximum at different warfarin concentrations were obtained 
from Figure 4.21. 
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Figure 4.23  Fluorescence spectra of HSA (1.0µM) in the absence and presence of 
increasing warfarin concentrations but with 8.0M urea in 0.06M sodium 
phosphate buffer, pH 7.0 at 25Ԩ incubated for 60 minutes, upon excitation at 
280nm. Warfarin concentrations from top to bottom (1-11) were: 0.0, 0.75, 3.0, 
3.5, 4.0, 5.0, 10.0, 15.0, 20.0, 30.0 and 40.0µM respectively. 
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Figure 4.24  Plots showing change in the relative fluorescence intensity at 342nm 
upon excitation at 280nm (A) and the emission maximum (B) of HSA in 8.0M 
urea against warfarin concentration. Data of the relative fluorescence intensity 
and emission maximum at different warfarin concentrations were obtained from 
Figure 4.23. 
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Figure 4.25  Plots showing change in the relative fluorescence intensity of HSA at 
the emission maximum with increasing warfarin concentrations at different urea 
concentrations when excited at (A) 280nm and (B) 295nm. Different urea 
concentrations used were: 0.0 (●), 3.0 (○), 3.5 (▲), 4.0 (ൈ), 4.5 (♦), 5.3 (◊), 6.5 
(■), 8.0 (□) M. 
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Figure 4.26  Plots showing change in the emission maximum of HSA with 
increasing warfarin concentrations at different urea concentrations when excited 
at (A) 280nm and (B) 295nm. Different urea concentrations used were: 0.0 (●), 
3.0 (○), 3.5 (▲), 4.0 (∆), 4.5 (ൈ), 5.3 (♦), 6.5 (◊) and 8.0 (■) M. 
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drug concentrations. However, at higher urea concentrations, a linear decrease in 
the fluorescence intensity was noticed throughout the drug concentration range 
(Figure 4.25A). Plots of relative fluorescence intensity versus drug concentration 
obtained in presence of 3.0, 3.5 and 4.0M urea concentrations showed little 
variation, among each other but were found different from that obtained in the 
absence of urea. There was a progressive decrease in the fluorescence quenching 
with the increase in urea concentration at each drug concentration as the plots 
moved upwards on the Y-axis and became linear at higher urea concentrations 
(Figure 4.25A). Since the decrease in the fluorescence intensity (fluorescence 
quenching) with increasing warfarin concentrations was suggestive of warfarin 
binding to HSA, any decrease in the fluorescence quenching in presence of urea 
indicated loss in the drug binding to the protein. A significant loss in drug binding 
was noticed in presence of ൒6.5M urea due to lesser degree of quenching 
throughout the drug concentration range. At the highest drug concentration 
(40µM), about 39% and 31% quenching were noticed in presence of 6.5 and 8M 
urea respectively against 80% quenching observed with native HSA (Figure 
4.25A). Similar conclusions can be drawn from Figure 4.40A where values of 
emission maximum have been plotted against warfarin concentration in presence 
of different concentrations of urea. The red shift became smaller at higher urea 
concentrations, indicating loss in drug binding to HSA.  
To validate these findings, fluorescence spectra were also recorded under similar 
conditions but upon excitation at 295nm and the spectra are shown in Figures 
4.27, 4.29, 4.31, 4.33, 4.35, 4.37 and 4.39. Both decrease in the fluorescence 
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intensity and significant red shift were noticed as shown in Figures 4.28, 4.30, 
4.32, 4.34, 4.36, 4.38 and 4.40. Presence of urea in the incubation mixture caused 
both decrease in the fluorescence quenching as well as red shift in the emission 
maximum (Figures 4.25B and 4.26B). Although these results were found similar 
to those obtained with 280nm excitation, at lower drug concentrations, smaller 
differences were observed at higher drug concentrations (Figures 4.25 and 4.26). 
For example, at 40µM drug concentration, about 31% and 48% quenching in the 
fluorescence intensity were noticed in presence of 8M urea, when monitored upon 
excitation at 280 and 295nm respectively (Figure 4.25A and B). Similarly, a red 
shift of 15 and 24nm was observed at 30µM drug concentration in presence of 
5.3M urea upon excitation at 280 and 295nm respectively (Figure 4.26A and B).  
Presence of urea decreased the binding of warfarin to HSA as revealed by the 
decrease in fluorescence quenching and red shift in the emission maximum 
observed in the presence of urea (Figures 4.25 and 4.26). Drug binding data were 
analyzed in the same way as suggested by Eftink and Ghiron (1982). Stern-
Volmer plots for warfarin-HSA interaction both in the absence and presence of 
different urea concentrations are shown in Figure 4.41. As can be seen from the 
figure, plots showed linearity at lower drug concentrations and significant 
deviation from linearity was noticed at higher drug concentrations. Values of the 
quenching constant (ܭ௦௩ሻ	as determined from the slope of initial linear parts of the 
plots are given in Table 4.1. A value of ܭ௦௩ (2.17ൈ 10ହ	Mିଵ) was obtained for 
warfarin-HSA interaction which was similar to those reported earlier for other 
drugs, known to bind site I of HSA (Wang et al., 2011; Abdollahpour et al., 2011) 
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Figure 4.27  Fluorescence spectra of HSA (1.0µM) in the absence and presence of 
increasing warfarin concentrations but with 3.0M urea in 0.06M sodium 
phosphate buffer, pH 7.0 at 25Ԩ incubated for 60 minutes, upon excitation at 
295nm. Warfarin concentrations from top to bottom (1-13) were: 0.0, 0.5, 0.75, 
1.0, 1.6, 2.0, 2.5, 3.5, 10.0, 15.0, 20.0, 30.0 and 40.0µM respectively. 
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Figure 4.28  Plots showing change in the relative fluorescence intensity at 342nm 
upon excitation at 295nm (A) and the emission maximum (B) of HSA in 3.0M 
urea against warfarin concentration. Data of the relative fluorescence intensity 
and the emission maximum at different warfarin concentrations were obtained 
from Figure 4.27. 
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Figure 4.29  Fluorescence spectra of HSA (1.0µM) in the absence and presence of 
increasing warfarin concentrations but with 3.5M urea in 0.06M sodium 
phosphate buffer, pH 7.0 at 25Ԩ incubated for 60 minutes, upon excitation at 
295nm. Warfarin concentrations from top to bottom (1-15) were: 0.0, 0.5, 1.0, 
1.3, 1.6, 2.0, 2.5, 3.0, 4.0, 5.0, 10.0, 15.0, 20.0, 30.0 and 40.0µM respectively. 
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Figure 4.30  Plots showing change in the relative fluorescence intensity at 341nm 
upon excitation at 295nm (A) and the emission maximum (B) of HSA in 3.5M 
urea against warfarin concentration. Data of the relative fluorescence intensity 
and the emission maximum at different warfarin concentrations were obtained 
from Figure 4.29. 
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Figure 4.31  Fluorescence spectra of HSA (1.8µM) in the absence and presence of 
increasing warfarin concentrations but with 4.0M urea in 0.06M sodium 
phosphate buffer, pH 7.0 at 25Ԩ incubated for 60 minutes, upon excitation at 
295nm. Warfarin concentrations from top to bottom (1-14) were: 0.0, 0.5, 0.75, 
1.3, 2.5, 3.0, 3.5, 4.0, 5.0, 10.0, 15.0, 20.0, 30.0 and 40.0µM respectively. 
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Figure 4.32  Plots showing change in the relative fluorescence intensity at 341nm 
upon excitation at 295nm (A) and the emission maximum (B) of HSA in 4.0M 
urea against warfarin concentration. Data of the relative fluorescence intensity 
and the emission maximum at different warfarin concentrations were obtained 
from Figure 4.31. 
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Figure 4.33  Fluorescence spectra of HSA (1.0µM) in the absence and presence of 
increasing warfarin concentrations but with 4.5M urea in 0.06M sodium 
phosphate buffer, pH 7.0 at 25Ԩ incubated for 60 minutes, upon excitation at 
295nm. Warfarin concentrations from top to bottom (1-11) were: 0.0, 0.75, 1.3, 
2.0, 3.0, 3.5, 10.0, 15.0, 20.0, 30.0 and 40.0µM respectively. 
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Figure 4.34  Plots showing change in the relative fluorescence intensity at 341nm 
upon excitation at 295nm (A) and the emission maximum (B) of HSA in 4.5M 
urea against warfarin concentration. Data of the relative fluorescence intensity 
and the emission maximum at different warfarin concentrations were obtained 
from Figure 4.33. 
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Figure 4.35  Fluorescence spectra of HSA (1.0µM) in the absence and presence of 
increasing warfarin concentrations but with 5.3M urea in 0.06M sodium 
phosphate buffer, pH 7.0 at 25Ԩ incubated for 60 minutes, upon excitation at 
295nm. Warfarin concentrations from top to bottom (1-10) were: 0.0, 0.75, 1.3, 
2.0, 3.5, 10.0, 15.0, 20.0, 30.0 and 40.0µM respectively. 
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Figure 4.36  Plots showing change in the relative fluorescence intensity at 343nm 
upon excitation at 295nm (A) and the emission maximum (B) of HSA in 5.3M 
urea against warfarin concentration. Data of the relative fluorescence intensity 
and the emission maximum at different warfarin concentrations were obtained 
from Figure 4.35. 
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Figure 4.37  Fluorescence spectra of HSA (1.0µM) in the absence and presence of 
increasing warfarin concentrations but with 6.5M urea in 0.06M sodium 
phosphate buffer, pH 7.0 at 25Ԩ incubated for 60 minutes, upon excitation at 
295nm. Warfarin concentrations from top to bottom (1-10) were: 0.0, 1.3, 2.0, 
3.5, 5.0, 10.0, 15.0, 20.0, 30.0 and 40.0µM respectively. 
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Figure 4.38  Plots showing change in the relative fluorescence intensity at 347nm 
upon excitation at 295nm (A) and the emission maximum (B) of HSA in 6.5M 
urea against warfarin concentration. Data of the relative fluorescence intensity 
and emission maximum at different warfarin concentrations were obtained from 
Figure 4.37. 
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Figure 4.39  Fluorescence spectra of HSA (1.8µM) in the absence and presence of 
increasing warfarin concentrations but with 8.0M urea in 0.06M sodium 
phosphate buffer, pH 7.0 at 25Ԩ incubated for 60 minutes, upon excitation at 
295nm. Warfarin concentrations from top to bottom (1-10) were: 0.0, 1.0, 2.5, 
3.0, 3.5, 10.0, 15.0, 20.0, 30.0 and 40.0µM respectively. 
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Figure 4.40  Plots showing change in the relative fluorescence intensity at 350nm 
upon excitation at 295nm (A) and the emission maximum (B) of HSA in 8.0M 
urea against warfarin concentration. Data of the relative fluorescence intensity 
and the emission maximum at different warfarin concentrations were obtained 
from Figure 4.39. 
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Figure 4.41  Stern-Volmer plots for tryptophan fluorescence quenching of HSA at 
increasing warfarin concentrations in the absence and presence of different urea 
concentrations; 0.0 (□), 3.0 (■), 3.5 (◊), 4.0 (♦), 4.5 (∆), 5.3 (▲), 6.5 (○) and 8.0 
(●) M urea.  
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Table 4.1 Values of the Stern-Volmer constant (Ksv) for tryptophan fluorescence 
quenching of HSA upon warfarin binding in the absence and presence of different 
urea concentrations. 
 
[Urea] M ࡷ࢙࢜ ሾۻି૚ሿ ࡾ૛ 
0.0 2.17ൈ 10ହ 0.992 
3.0 1.39ൈ 10ହ 0.9982 
3.5 1.06ൈ 10ହ 0.9917 
4.0 9.03ൈ 10ସ 0.993 
4.5 1.09ൈ 10ହ 0.9908 
5.3 6.39ൈ 10ସ 0.9956 
6.5 1.88ൈ 10ସ 0.9929 
8.0 5.34ൈ 10ଷ 0.8828 
																																			Rଶ ൌ Correlation	coefϐicient 
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There was a significant decrease in ܭ௦௩ value with increasing urea concentrations. 
Decrease in the  ܭ௦௩ value with increasing urea concentrations suggested the 
increase in the distance between excited fluorophore (Trp) and the ligand 
(warfarin). Therefore the tertiary structure of the protein was destabilized at 
higher urea concentrations. 
Apparent binding constant, ܭ௕ for warfarin-HSA interaction were determined 
from the plots shown in Figure 4.42 and the values of ܭ௕ are listed in Table 4.2. 
Value of binding constant, 2.1ൈ 10ହ Mିଵ	as obtained in this study was similar to 
the one reported earlier (Wilting et al., 1980; Fleury et al., 1997). The binding 
constant decreased from 2.1ൈ	10ହ Mିଵ under native conditions to 4.7ൈ	10ଷ Mିଵ 
in the presence of 5.3M urea. Although, there was a decrease in both Stern-
Volmer constant (ܭ௦௩) and apparent binding constant (ܭ௕) with increasing urea 
concentrations, it was more pronounced in ܭ௕ at higher urea concentrations (e.g. 
5.3M). These results suggested the sensitivity of warfarin binding site to urea as 
alteration in the three-dimensional structure of HSA markedly affected its drug 
binding ability.   
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Figure 4.42  Plots of Log [(F0-F)/ F] versus Log [Warfarin] in the absence and 
presence of different urea concentrations. Values of ܨ଴	and F were taken from 
Figure 4.25 A. Different urea concentrations used were: 0.0 (●), 3.5 (○), 4.0 (▲), 
4.5 (∆) and 5.3 (♦) M urea.  
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Table 4.2 Values of the binding constant (Kb) for the warfarin-HSA complex in 
the absence and presence of different urea concentrations. 
 
[Urea] M ۹܊ሾۻି૚ሿ ܀૛ 
0.0 2.1 ൈ 10ହ 0.9755 
3.5 1.7 ൈ 10ହ 0.9832 
4.0 1.4 ൈ 10ହ 0.9864 
4.5 1.1 ൈ 10ସ 0.959 
5.3 4.7 ൈ 10ଷ 0.9962 
																																												Rଶ ൌ Correlation	coefϐicient 
 
 
 
 
 
 
 
